Display options
Cite
Ha J, Jo K, Kang B, et al. Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis. Endocrinol Metab (Seoul). 2016;31(3):476-479doi: 10.3803/EnM.2016.31.3.476.
Ha, J., Jo, K., Kang, B., Kim, M. H., & Lim, D. J. (2016). Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis. Endocrinology and metabolism (Seoul, Korea), 31(3), 476-479. https://doi.org/10.3803/EnM.2016.31.3.476
Ha, Jeonghoon, et al. "Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis." Endocrinology and metabolism (Seoul, Korea) vol. 31,3 (2016): 476-479. doi: https://doi.org/10.3803/EnM.2016.31.3.476
Ha J, Jo K, Kang B, Kim MH, Lim DJ. Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis. Endocrinol Metab (Seoul). 2016 Sep;31(3):476-479. doi: 10.3803/EnM.2016.31.3.476. Epub 2016 Jul 26. PMID: 27469067; PMCID: PMC5053062.
Copy Download .nbib Format: NLM
Share it on

Endocrinol Metab (Seoul). 2016 Sep;31(3):476-479. doi: 10.3803/EnM.2016.31.3.476. Epub 2016 Jul 26.

Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis.

Endocrinology and metabolism (Seoul, Korea)

Jeonghoon Ha, Kwanhoon Jo, Borami Kang, Min Hee Kim, Dong Jun Lim

Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. [email protected].

PMID: 27469067 PMCID: PMC5053062 DOI: 10.3803/EnM.2016.31.3.476

Abstract

Cholestyramine (CS) is an ion exchange resin, which binds to iodothyronines and would lower serum thyroid hormone level. The use of CS added to conventional antithyroid drugs to control thyrotoxicosis has been applied since 1980's, and several studies indicate that using CS in combination with methimazole (MZ) produces a more rapid decline in serum thyroid hormones than with only MZ treatment. Our recent retrospective review of five patients taking high dose MZ and CS, compared to age-, gender-, initial free thyroxine (T4) level-, and MZ dose-matched 12 patients with MZ use only, showed more rapid decline of both free T4 and triiodothyronine levels without more adverse events. CS could be safely applicable short-term adjunctive therapy when first-line antithyroid medications are not enough to adequately control severe thyrotoxicosis or side effects of antithyroid drug would be of great concern.

Keywords: Cholestyramine resin; Graves disease; Thyrotoxicosis

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

  1. J Clin Endocrinol Metab. 1986 Jul;63(1):125-8 - PubMed
  2. Thyroid. 2009 Jun;19(6):559-63 - PubMed
  3. N Engl J Med. 2005 Mar 3;352(9):905-17 - PubMed
  4. Clin Endocrinol (Oxf). 2005 May;62(5):521-4 - PubMed
  5. J Endocrinol Invest. 1987 Jun;10(3):291-5 - PubMed
  6. Endocrinol Metab (Seoul). 2015 Dec;30(4):620-5 - PubMed
  7. Clin Endocrinol (Oxf). 1993 Jan;38(1):39-43 - PubMed
  8. J Clin Endocrinol Metab. 1996 Sep;81(9):3191-3 - PubMed
  9. Endocr J. 1995 Oct;42(5):697-704 - PubMed
  10. Thyroid. 2008 Oct;18(10):1115-7 - PubMed

Publication Types